Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results